NCT04420754View on ClinicalTrials.gov

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

August 4, 2026

Study Completion Date

August 4, 2030

Conditions
Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer
Interventions
BIOLOGICAL

AIC100 CAR T Cells

Autologous CAR T cells directed against ICAM-1

Trial Locations (4)

10065

Weill Cornell Medical College, New York

60611

Northwestern Memorial Hospital, Chicago

77030

MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, City of Hope Medical Center, Duarte

Sponsors
All Listed Sponsors
lead

AffyImmune Therapeutics, Inc.

INDUSTRY

NCT04420754 - Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | Biotech Hunter | Biotech Hunter